CARD10 Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA5111422-Each-of-1 | In Stock | ₹ 48,905.50 |
PIPA5111422 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 48,905.50
GST (18%): ₹ 8,802.99
Total Price: ₹ 57,708.49
Antigen
CARD10
Classification
Polyclonal
Formulation
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2
Gene Accession No.
Q9BWT7
Gene Symbols
CARD10
Immunogen
Recombinant Protein corresonding to Human CARD10
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG
Applications
Immunocytochemistry
Conjugate
Unconjugated
Gene
CARD10
Gene Alias
AI449026; Bcl10 binding protein and activator of NFKB; bcl10-interacting MAGUK protein 1; Bimp1; Card10; CARD-containing MAGUK 3 protein; CARD-containing MAGUK protein 3; Carma 3; Carma3; caspase recruitment domain family member 10; caspase recruitment domain family, member 10; caspase recruitment domain-containing protein 10
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
29775
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Form
Liquid
Related Products
Description
- Immunogen sequence: LTTLTSLEGT KALLEVQLQR AQGGTCLKAC ASSHSLCSNL SSTWSLSEFP SPLGGPEATG EAAVMGGPEP HNSEEATDSE KEINRLSILP F CARMA proteins belong to the membrane-associated guanylate kinase-like (MAGUK) family of proteins that can function as molecular scaffolds that assist assembly of signal transduction molecules
- CARMA1, CARMA2, and CARMA3 share high degrees of sequence and functional homology, but their tissue-specific distribution suggests that they serve distinct biological functions in different cell types
- As with CARMA1, the CARD domain of CARMA3 has been shown to specifically interact with BCL10, a protein known to function as a positive regulator of cell apoptosis and NF-Kappa-B activation
- When expressed in cells, this protein binds to BCL10 and activates NF-Kappa-B Recent experiments have shown that CARMA3 is required for EGF-induced NF-Kappa-B activation and contributes to tumor growth in vivo, suggesting that CARMA3 may serve as a new therapeutic target for the treatment of EGFR-driven tumors.